Clinical Trials Browser

Urinary Bladder Neoplasms

Turcot syndrome, Colorectal Neoplasms

Nasopharyngeal Carcinoma

Advanced Breast Cancer

Pancreatic Cancer Metastatic

Advanced Lung Cancer

Nasopharyngeal Carcinoma

Breast Neoplasms, Triple Negative Breast Neoplasms

Carcinoma, Non-Small-Cell Lung

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Meningeal Carcinomatosis

Carcinoma, Renal Cell

Advanced Malignant Solid Tumors

Small Cell Lung Carcinoma

Colorectal Neoplasms

Nasopharyngeal Carcinoma

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms, Papillomavirus Infections

Nasopharyngeal Carcinoma

Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Squamous Cell Carcinoma of Head and Neck, Neoplasm Metastasis, Recurrence

Locally Advanced Rectal Cancer

Carcinoma, Non-Small-Cell Lung

Carcinoma, Renal Cell

Carcinoma, Non-Small-Cell Lung

Skin Neoplasms

Nasopharyngeal Carcinoma

Carcinoma, Renal Cell

Muscle Invasive Bladder Cancer (MIBC)

Pancreatic Neoplasms

Uterine Cervical Neoplasms

Triple Negative Breast Neoplasms

Carcinoma, Renal Cell

Head and Neck Neoplasms

Small Cell Lung Carcinoma

Local Advanced Non-small Cell Lung Cancer

Colorectal Neoplasms

Breast Neoplasms

Nasopharyngeal Carcinoma

Oropharyngeal Neoplasms

Small Cell Lung Cancer Limited Stage

Breast Neoplasms

Esophageal Squamous Cell Carcinoma

Small Cell Lung Carcinoma

Squamous Cell Carcinoma of Head and Neck

Uterine Cervical Neoplasms, Neoplasm Metastasis, Recurrence

Clinical Trials

HOPE-07-MIBC

PICC-3

LIGHT

Metronomic Oral Paclitaxel Monotherapy and Combined Immunotherapy for Advanced HER2-Negative Breast Cancer: A Two-Stage Dose Exploration and Expansion Trial

A Phase Ib/II Clinical Study of Regorafenib Combined With Toripalimab and Albumin-bound Paclitaxel for the Third-line Treatment of Advanced Pancreatic Cancer

A Phase II Clinical Study Evaluating the Combination Therapy of JS212 in Patients With Advanced Lung Cancer

Maintenance Therapy With Toripalimab and Capecitabine Versus Capecitabine Alone in High-risk Nasopharyngeal Carcinoma

NeoTOP

neoR-TORCH

Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial

SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal Carcinoma

Immune Checkpoint Inhibitor Combined With Pemetrexed Intrathecal Injection for Leptomeningeal Metastasis From Solid Tumors

TRIPLE-PATH

Phase II Study of JS212/JS213 as Monotherapy and in Combination in Patients With Advanced Malignant Solid Tumors

Low-dose Radiotherapy Combined With Concurrent Chemotherapy, Toripalimab and Tifcemalimab in the Treatment of ES-SCLC

Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver Metastases

Becotatug Vedotin Plus PD-1 Monoclonal Antibody and Radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma

Toripalimab（JS001） as Monotherapy in Participants With POLE or POLD-1 Mutated and Non-MSI-H Advanced Solid Tumors

(NeoScorch HN)

GAPP Induction and Concurrent Chemoradiotherapy for High-risk Locoregionally Advanced NPC.

EC-CRT-008

FACT-TN

WOLF

TORCH-iTNT

Efficacy and Safety of Sacituzumab Tirumotecan (SKB264) in Combination With Toripalimab in Patients With Initially Unresectable Stage III NSCLC

Fasting-Mimicking Diet Combined With IO-TKI Combination Therapy in Patients With Metastatic Renal Cell Carcinoma

Study on the Efficacy and Safety of JSKN016 as Neoadjuvant Therapy in Resectable Stage II-III Non-small Cell Lung Cancer Patients

Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy

Chidamide in Combination With Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma.

Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma

Probiotics Combined With Targeted Therapy Plus Immunotherapy in Bladder-Preserving Setting for Patients With MIBC

Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic Cancer

The Effect of Toripalimab Plus Radiotherapy in Patients With Operable Stage II-IIIA (N+) Non Small Cell Lung Cancer

Anti-PD-1 Antibody Combined With Histone Deacetylase Inhibitor in Patients With Advanced Cervical Cancer

Clinical Study of Therapeutic Immunological Agent for EBV-positive Advanced Malignant Tumors

NEOTRIO-2

PLUTO

A Single-center Phase II Study to Investigate the Immune Maintenance Therapy Pattern in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Who Have Achieved MPR After Neoadjuvant Immunotherapy Combined With Chemotherapy

Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer

InTRist

Combination Immunotherapy for the Treatment of Chemotherapy-refractory Metastatic MSS CRC

Phase II Exploratory Study of Toripalimab Combined With SBRT in HER2-Negative Breast Cancer Patients With Insensitivity to Neoadjuvant Chemotherapy

Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC)

Toripalimab in Combination With Standard Treatment for Human Papillomavirus (HPV) Positive Throat Cancer

Study of Toripalimab for Limited-Stage Small Cell Lung Cancer Following Concurrent Chemoradiotherapy

Neoadjuvant Therapy Combined With Trastuzumab Rezetecan and Toripalimab for HR+/HER2-low Breast Cancer (NEOTORCH-BREAST 08)

TD-NEOE3V3

Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction

SHINE

A Phase II Study of Utidelone With Toripalimab in Advanced Cervical Cancer